S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Idera Pharmaceuticals Stock Forecast, Price & News

-0.02 (-4.58%)
(As of 07/1/2022 05:43 PM ET)
Today's Range
50-Day Range
52-Week Range
83,495 shs
Average Volume
704,172 shs
Market Capitalization
$23.20 million
P/E Ratio
Dividend Yield
Price Target

Idera Pharmaceuticals Stock Forecast (MarketRank)

Analyst Rating
Short Interest
4.89% of Float Sold Short
Dividend Strength
News Sentiment
1.43mentions of Idera Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.84 out of 5 stars

Medical Sector

1246th out of 1,429 stocks

Biological Products, Except Diagnostic Industry

191st out of 217 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive IDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Idera Pharmaceuticals logo

About Idera Pharmaceuticals (NASDAQ:IDRA)

Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

IDRA Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Net Income
$98.09 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.45 million
Cash Flow
$2.43 per share
Book Value
$0.56 per share


Free Float
Market Cap
$23.20 million

Social Links

Idera Pharmaceuticals Frequently Asked Questions

How has Idera Pharmaceuticals' stock price performed in 2022?

Idera Pharmaceuticals' stock was trading at $0.57 at the beginning of the year. Since then, IDRA shares have decreased by 23.2% and is now trading at $0.4380.
View the best growth stocks for 2022 here

When is Idera Pharmaceuticals' next earnings date?

Idera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Idera Pharmaceuticals

How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced its quarterly earnings data on Thursday, May, 5th. The biotechnology company reported ($0.08) earnings per share for the quarter.
View Idera Pharmaceuticals' earnings history

When did Idera Pharmaceuticals' stock split? How did Idera Pharmaceuticals' stock split work?

Idera Pharmaceuticals's stock reverse split on Monday, July 30th 2018. The 1-8 reverse split was announced on Friday, July 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 27th 2018. An investor that had 100 shares of Idera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

Who are Idera Pharmaceuticals' key executives?

Idera Pharmaceuticals' management team includes the following people:
  • Mr. Vincent J. Milano, Pres, CEO & Director (Age 58, Pay $794.24k)
  • Mr. John J. Kirby CPA, Sr. VP & CFO (Age 50, Pay $477.41k) (LinkedIn Profile)
  • Mr. Daniel B. Soland, Sr. VP & COO (Age 66, Pay $552.83k) (LinkedIn Profile)
  • Mr. Bryant David Lim, Sr. VP, Gen. Counsel & Corp. Sec. (Age 51, Pay $480.96k) (LinkedIn Profile)
  • Ms. Jill Conwell, Sr. VP of Investor Relations & Corp. Communications
  • Ms. Elizabeth Eberhardt, Sr. VP of Product Leadership
  • Dr. Shah Rahimian M.D., Ph.D., Medical Director & Global Clinical Lead for Oncology
  • Dr. Joanna Caroline Horobin Ch.B, M.B., Advisor (Age 67)
  • Dr. Sudhir Agrawal D.Phil., DPHIL, F.R.S.C., Scientific Advisor (Age 68)
  • Mr. Louis J. Arcudi III, M.B.A., MBA, Adviser (Age 61)

What is Vincent Milano's approval rating as Idera Pharmaceuticals' CEO?

7 employees have rated Idera Pharmaceuticals CEO Vincent Milano on Glassdoor.com. Vincent Milano has an approval rating of 88% among Idera Pharmaceuticals' employees.

What other stocks do shareholders of Idera Pharmaceuticals own?

What is Idera Pharmaceuticals' stock symbol?

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

How do I buy shares of Idera Pharmaceuticals?

Shares of IDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Idera Pharmaceuticals' stock price today?

One share of IDRA stock can currently be purchased for approximately $0.44.

How much money does Idera Pharmaceuticals make?

Idera Pharmaceuticals (NASDAQ:IDRA) has a market capitalization of $23.20 million and generates $1.45 million in revenue each year. The biotechnology company earns $98.09 million in net income (profit) each year or ($0.42) on an earnings per share basis.

How many employees does Idera Pharmaceuticals have?

Idera Pharmaceuticals employs 32 workers across the globe.

When was Idera Pharmaceuticals founded?

Idera Pharmaceuticals was founded in 1989.

How can I contact Idera Pharmaceuticals?

Idera Pharmaceuticals' mailing address is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. The official website for Idera Pharmaceuticals is www.iderapharma.com. The biotechnology company can be reached via phone at (484) 348-1600, via email at [email protected], or via fax at 617-679-5592.

This page (NASDAQ:IDRA) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.